Brief: Oncosec Announces Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Medical Incorporated

09/11/2020 13:52

Nov 9 (Reuters) - OncoSec Medical Inc  ONCS.O :
    * ONCOSEC ANNOUNCES POSITIVE INTERIM DATA FROM KEYNOTE-695
TRIAL
IN ANTI-PD-1 CHECKPOINT REFRACTORY METASTATIC MELANOMA
    * ONCOSEC MEDICAL INC - 30% OVERALL RESPONSE RATE (ORR) AND
6%
COMPLETE RESPONSE (CR) RATE ACHIEVED
    * ONCOSEC MEDICAL INC - 35% ORR ACHIEVED IN PATIENTS WITH
STAGE IV
M1C OR M1D DISEASE
    * ONCOSEC MEDICAL INC - TAVO + PEMBROLIZUMAB DEMONSTRATED
DURABLE
RESPONSES FOR UP TO TWO YEARS
    * ONCOSEC MEDICAL INC - ALSO ANNOUNCED PRE-CLINICAL DATA
SHOWING
THAT CORVAX12 TRIGGERS AN IMMUNE RESPONSE AGAINST SARS-COV-2
VIRUS

Source text for Eikon:  ID:nPn3Dqhp4a 
Further company coverage:  ONCS.O 

 ((Reuters.Briefs@thomsonreuters.com;))